Curriculum vitae - Heidelberg University Hospital

Curriculum vitae
Ad personam
Prof. Wolfgang Wick, MD
Medical Director, Neurology Clinic
INF 400, D-69120 Heidelberg
Phone: 06221-567075
Fax: 06221-567554
E-Mail: neuroonkologie@med.uni-heidelberg.de
married to Antje Wick, MD
two children
Major




clinical interests:
Primary brain tumors (glioma and lymphoma)
Metastatic brain tumors
Neurological complications of cancer
Neuroimmunology (multiple sclerosis, other neurological autoimmune
disease)
→ Neurooncology ward and outpatient clinic, Headclinic Heidelberg
Major research interests:
 Clinical trials
 Targeted antiangiogenic therapies
 Prognostic and predictive biomarkers
 Immunotherapy
→ Study center at the NCT and outpatient clinics; Clinical Cooperation Unit
Neurooncology, German Cancer Research Center, Heidelberg
Education
09/80 – 05/89
06/89 – 09/90
Carl-von-Ossietzky Gymnasium, Bonn
Civil service: St. Marienhospital Bonn
10/90
09/93
07/94
09/96
06/97
11/97
University of Bonn: Medicine
King´s College London, Great Britain
University of Bonn
Harvard Medical School, Boston, USA
University of Bonn
Examination
–
–
–
–
–
08/93
06/94
08/96
05/97
11/97
05/98
Appointments
01/98 – 06/99
Doctoral thesis at the Institute for Neuropathology (Prof. Dr.
O.D. Wiestler) at the University of Bonn (Summa cum laude)
Internship at the Department of Neurology, University of
Tübingen (Chairman: Prof. Dr. J. Dichgans)
07/99 – 12/01
01/02 – 12/02
Resident at the Department of Neurology, University of Tübingen
Resident at the Department of Psychiatry, University of Tübingen
(Chairman: Prof. Dr. G. Buchkremer)
04/03
Board certification in Neurology
07/03
Habilitation and venia legendi for Neurology
08/03 – 10/08
Head of the Research Group Hematopoietic stem cells and
glioma of the State of Baden-Württemberg
since 08/04
Attending in Neurology
since 10/2005
Steering Committee of the Brain Tumor Group of the EORTC
04-12/06
Vice Chairman, Dep. of General Neurology, University of
Tübingen, Germany (Chairman: Prof. Dr. M. Weller)
01/07 – 09/14
Chairman Dep. of Neurooncology/NCT and Professor of Clinical
Neurooncology, University of Heidelberg
since 07/2007
Steering Committee of the Neurooncology Working Group (NOA)
of the German Cancer Society
02/2008-02/2009 Chair-elect of the Brain Tumor Group of the EORTC
09/2008
Member of the EANO Board
03/2009
Chairman of the EORTC Brain Tumor Group
03/2009
Member of the of the Grant Application Council for Young
Scientists of the German Cancer Aid
01/2010
Member of the Board of Directors at the NCT
01/2010-04/2014 Member of the Board of Directors European Cancer Organization
(ECCO)
06/2014
Chair of the NOA
10/2014
Chairman General Neurology Heidelberg
Publications
since 1998
>250 peer-reviewed publications
http://www.ncbi.nlm.nih.gov/sites/entrez/wick w
e.g. Annals of Neurology, Brain, Cancer Research, Journal of
Clinical Investigation, Journal of Clinical Oncology, The
Lancet Oncology, The New England Journal of Medicine,
Nature, Nature Medicine, Neurology, and Neurooncology
Scholarships and awards
1991 – 1997
1993 - 1994
1996 - 1997
1996
1997
2001
2003
2005
2006
Scholar of the German National Scholarship Foundation
Grant of the German National Scholarship Foundation for the
studies in London, UK
Grant of the German National Scholarship Foundation for the
studies in Boston, USA
Grant of the Boehringer Ingelheim Fonds
Best doctoral thesis of the Medical Faculty at the University of
Bonn
Attempto-Award for Neurobiology of the University of Tübingen
Novartis-Award for Clinical Research
Sibylle-Assmus Award for Neurooncology
Pette Award of the German Society of Neurology
2
2009
Memberships
Ad hoc referee
Editorial Board
Coordination of
clinical trials
Glioblastoma
(LKP/PI only and
associated
preclinical and
clinical
references)
Key Note Lecture World Federation of Neurooncology Meeting,
Japan
Fellow of the Faculty of the 1000 Medicine
American Society of Clinical Oncology (ASCO); Deutsche
Gesellschaft für Neurologie; Deutsche Gesellschaft für
Gentherapie; Neuro-Onkologische Arbeitsgemeinschaft (NOA) der
Deutschen Krebsgesellschaft (DKG); Deutsche Krebshilfe,
European Association of Neuro Oncology (EANO); Faculty of the
European Society of Medical Oncology (ESMO); Steering
Committee of the Brain Tumor Group of the European
Organisation for Research and Treatment of Cancer (EORTC)
American Journal of Pathology; Brain; Brain Research; British
Journal of Cancer; Cancer Investigation; Cancer Letters; Cancer
Research; Cellular Physiology and Biochemistry; Clinical Cancer
Research; Critical Reviews in Oncology/Hematology; European
Journal of Cancer; Experimental Neurology, Glia; International
Journal of Cancer; Journal of Neurochemistry; Leukemia;
Microscopy Research and Technique; Neurology; Neurooncology;
Oncogene; Pharmacology & Therapeutics; Targeted Oncology;
Therapy; The Lancet; The Lancet Oncology; Association for
International Cancer Research, Great Britain; BMBF; Dutch
Cancer Society; German Cancer Aid; German National Scholarship
Foundation; German Research Foundation
Neurooncology (Handling Editor), CNS Oncology, J
Neurochemistry (Handling Editor)
http://www.klinikum.uni-heidelberg.de/Studien.108964.0.html
EORTC 26082: Radiation therapy and concurrent plus adjuvant
Temsirolimus (CCI-779)/RT followed by CCI-779 versus chemoirradiation with temozolomide in newly diagnosed glioblastoma
without methylation of the MGMT gene promoter – a randomized
multicenter, open-label, Phase II study. (Ref. 115)
NOA-08: Temozolomid (one week on/one week off) versus
Strahlentherapie
in
der
Primärtherapie
anaplastischer
Astrozytome und Glioblastome bei älteren Patienten: eine
randomisierte Phase III-Studie (Methvsalem). (Ref. 114)
S039: Enzastaurin (LY317615) Before and Concomitant with
Radiation Therapy, Followed by Enzastaurin Maintenance
Therapy in Subjects with Newly Diagnosed Glioblastoma – a
Multicenter, Open-label, Uncontrolled Phase II Study. (Ref. 56)
DIRECTOR: Dose-intensified rechallenge with temozolomide, one
week on, one week off in patients with recurrent or progressive
glioblastoma. (Ref. 33, 62)
UKT-05: Chemoradiotherapy of Newly Diagnosed Glioblastoma
with Intensified Temozolomide. (Ref. 66, 117)
3
APG-101: A phase II, randomized, open-label, multi-centre
study of weekly APG101 + reirradiation versus irradiation in the
treatment of patients with first or second progression of
glioblastoma; Prüfplannummer: APG101_CD_002.
EORTC 26101: Phase II trial exploring the sequence of
bevacizumab and lomustine in patients with first recurrence of a
glioblastoma. (Ref. 84, 89)
NOA-12: A phase I/II, randomized, open-label, multi-centre
study of BIBF1120 + reirradiation (R-RT) versus reirradiation in
the treatment of patients with first or second progression of
glioblastoma.
EORTC 26054: Phase III trials comparing no adjuvant
chemotherapy versus adjuvant therapy until progression for
anaplastic glioma without 1p/19q loss. An EORTC/NCI-C/RTOG
intergroup trial.
Randomized
Phase
III
Trial
of
Sequential
Anaplastic Glioma NOA-04:
Radiochemotherapy of Anaplastic Glioma With PCV or
(PI/LKP only)
Temozolomide. (Ref. 77)
plus > 20 trials in brain tumors and sciatica as investigator or
local PI
Heidelberg, October 1st 2014
Prof. Wolfgang Wick, MD
4
Bibliography
1996
1.
1998
2.
1999
3.
4.
5.
6.
2000
7.
8.
9.
10.
2001
11.
12.
13.
14.
Wick W, Petersen I, Schmutzler RK, Wolfarth B, Lenartz D, Bierhoff E, Hummerich
J, Muller DJ, Stangl AP, Schramm J, Wiestler OD, von Deimling A. Evidence for a
novel tumor suppressor gene on chromosome 15 associated with progression to a
metastatic stage in breast cancer. Oncogene 1996;12:973-978
Wick W, Wagner S, Kerkau S, Dichgans J, Tonn JC, Weller M. BCL-2 promotes
migration and invasiveness of human glioma cells. FEBS Lett 1998;440:419-424
Wick W, Grimmel C, Wagenknecht B, Dichgans J, Weller M. Betulinic acid-induced
apoptosis in glioma cells: a sequential requirement for new protein synthesis,
formation of reactive oxygen species, and caspase processing. J Pharmacol Exp
Ther 1999;289:1306-1312
Wick W, Furnari FB, Naumann U, Cavenee WK, Weller M. PTEN gene transfer in
human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis.
Oncogene 1999;18:3936-3943
Pohl U, Wick W, Weissenberger J, Steinbach JP, Dichgans J, Aguzzi A, Weller M.
Characterization of Tu-2449, a glioma cell line derived from a spontaneous tumor
in GFAP-v-src-transgenic mice: comparison with established murine glioma cell
lines. Int J Oncol 1999;15:829-834
Ständer M, Naumann U, Wick W, Weller M. TGF-β and p21: multiple molecular
targets of decorin-mediated suppression of neoplastic growth. Cell Tissue Res
1999;296:221-227
Platten M, Wick W, Wild-Bode C, Aulwurm S, Dichgans J, Weller M. Transforming
growth factors β1 (TGF-β1) and TGF-β2 promote glioma cell migration via upregulation of αVβ3 integrin expression. Biochem Biophys Res Commun
2000;268:607-611
Schmidt F, Wick W, Herrlinger U, Dichgans J, Weller M. Treosulfan chemotherapy
for recurrent malignant glioma. J Neuro-Oncol 2000;49:231-234
Von Deimling A, Fimmers R, Schmidt MC, Bender B, Fassbender F, Nagel J, Jahnke
R, Kaskel P, Duerr E-M, Koopmann J, Mainz D, Schild S, Vogel Y, Wick W, Platten M,
Müller D, Przkora R, Waha A, Rollbrocker B, Wellenreuther R, Meyer Puttlitz B,
Schmidt O, Mollenhauer J, Stangl AP, Lenartz D, von Ammon K, Henson JW,
Schramm J, Louis DN, Wiestler OD. Comprehensive allelotype and genetic analysis
of 466 human nervous system tumors. J Neuropathol Exp Neurol 2000;59:544-558
Wick W, Hochberg F, O’Sullivan J, Goessling A, Hughes A, Cher L. L-Dopa- resistant
parkinsonism syndrome following cerebral radiation therapy for neoplasm. Oncol
Rep 2000;7:1367-1370
Weller M, Streffer J, Wick W, Kortmann RD, Heiss E, Küker W, Meyermann R,
Dichgans J, Bamberg M. Preirradiation gemcitabine chemotherapy for newly
diagnosed glioblastoma: a phase II study. Cancer 2001;91:423-427
Wild-Bode C, Weller M, Rimner A, Dichgans J, Wick W. Sublethal irradiation
promotes migration and invasiveness of glioma cells: implications for radiotherapy
of human glioblastoma. Cancer Res 2001;61:2744-2750
Platten M, Wild-Bode C, Wick W, Leitlein J, Dichgans J, Weller M. N-[3,4dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits TGF-β release and
reduces migration and invasiveness of human malignant glioma cells. Int J Cancer
2001;93:53-61
Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bähr M, Ohgaki
H, Ashkenazi A, Weller M. The soluble decoy receptor-3 is expressed by malignant
5
15.
16.
17.
18.
19.
20.
21.
22.
2002
23.
24.
25.
26.
27.
28.
29.
30.
2003
31.
gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer
Res 2001;61:2759-2765
Bähr O, Wick W, Weller M. Modulation of MDR/MRP by wild-type and mutant p53.
J Clin Invest 2001;107:643-645
Wick W, Grimmel C, Wild-Bode C, Platten M, Arpin M, Weller M. Ezrin-dependent
promotion of glioma cell clonogenicity, motility and invasion mediated by BCL-2
and TGF-β2. J Neurosci 2001;21:3360-3368
Wild-Bode C, Weller M, Wick W. Molecular determinants of glioma cell migration
and invasion. J Neurosurg 2001;94:978-984
Naumann U, Kügler S, Wolburg H, Wick W, Rascher G, Schulz JB, Conseiller E,
Bähr M, Weller M. Chimeric tumor suppressor 1 (CTS1), a p53-derived chimeric
tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy
with irradiation and CD95 ligand. Cancer Res 2001;61:5833-5842
Wick W, Platten M, Weller M. Glioma cell invasion: regulation of
metalloproteinase activity by TGF-β. J Neuro-Oncol 2001;53:177-185
Platten M, Wick W, Wischhusen J, Weller M. N-[3,4-dimethoxycinnamoyl]anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase
(iNOS) expression and activity induced by interferon-γ (IFN-γ). Br J Pharmacol
2001;134:1279-1284
Weller M, Wick W, Platten M. Role of TGF-β in oncogenesis (Editorial). Microscop
Res Techn 2001;52:353
Platten M, Wick W, Weller M. Malignant glioma biology: role for TGF-β in growth,
motility, angiogenesis and immune escape. Microscop Res Techn 2001;52:401-410
Wick W, Wick A, Schulz JB, Dichgans J, Rodemann HP, Weller M. Prevention of
irradiation-induced glioma cell invasion by temozolomide involves caspase 3
activity and cleavage of focal adhesion kinase. Cancer Res 2002;62:1915-1919
Wick W, Hermisson M, Küker WM, Kortmann RD, Duffner F, Dichgans J, Bamberg
M, Weller M. Neoadjuvant gemcitabine/treosulfan chemotherapy for newly
diagnosed glioblastoma. A phase II study. J Neuro-Oncol 2002;59:151-155
Wick W, Stock J, Seyfried J, Baumgart J, Wüllner U, Weller M. CD95/CD95 ligandindependent potentiation of treosulfan cytotoxicity by a glutathione depleting
agent, BSO, in malignant glioma cells in vitro and in vivo. Int J Oncol 2002;21:213200
Herrlinger U, Felsberg J, Küker W, Bornemann A, Plasswilm L, Knobbe CB, Strik H,
Wick W, Meyermann R, Dichgans J, Bamberg M, Reifenberger G, Weller M.
Gliomatosis cerebri. Molecular pathology and clinical course. Ann Neurol
2002;52:390-399
Wick A, Wick W, Waltenberger J, Weller M, Dichgans J, Schulz JB. Hypoxic
neuroprotection requires sequential activation of vascular endothelial growth
factor receptor and Akt. J Neurosci 2002;22:6401-6407
Fulda S*, Wick W*, Weller M, Debatin KM. Smac agonists sensitize for
TRAIL/Apo2L- or anticancer drug-induced apoptosis and induce regression of
human glioma xenografts. Nat Med 2002;8:808-815 (*geteilte Erstautorenschaft)
Nylandsted J, Wick W, Hirt UA, Brand K, Rohde M, Leist M, Weller M, Jäättelä M.
Eradication of glioblastoma and breast and colon carcinoma xenografts by Hsp70
depletion. Cancer Res 2002;62:7139-7142
Wick W, Weller M. Zur Rolle der Chemotherapie in der Behandlung maligner
Gliome. Journal Onkologie 2002;6:26-30
Hartmann C, Müller W, Laß U, Stockhammer F, von Eckardstein K, Veelken J,
Jeuken J, Wick W, von Deimling A. No preferential loss of paternal 19q alleles in
oligodendroglial tumors. Ann Neurol 2003;54:256-258
6
32.
33.
34.
35.
2004
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
2005
46.
47.
48.
49.
Brötz D, Küker W, Maschke E, Wick W, Dichgans J, Weller M. A prospective trial of
mechanical physiotherapy for lumbar disk prolapse. J Neurol 2003 250:746-749
Rieger J, Wick W, Weller M. Human malignant glioma cell lines express
semaphorins and their receptors, neuropilins and plexins. Glia 2003;42:379-389
Naumann U, Schmidt F, Wick W, Frank B, Weit S, Gillissen B, Daniel P, Weller M.
Adenoviral natural born killer (NBK) gene therapy of malignant glioma. Hum Gene
Ther 2003;14:1235-1246
Bähr O, Rieger J, Duffner F, Meyermann R, Weller M, Wick W. P-glycoprotein and
multidrug resistance-associated protein mediate specific patterns of multidrug
resistance in malignant glioma cell lines, but not in primary glioma cells. Brain
Pathol 2003;13:482-494
Naumann U, Wick W, Beschorner R, Meyermann R, Weller M. Expression and
functional activity of osteoprotegerin in human malignant gliomas. Acta
Neuropathol 2004;107:17-22
Wick W, Steinbach JP, Küker WM, Dichgans J, Bamberg M, Weller M. One week
on/one week off: a novel active regimen of temozolomide for recurrent
glioblastoma. Neurology 2004;62:2113-2115
Wick W, Wick A, Küker W, Dichgans J, Weller M. Intracranial metastatic
esthesioneuroblastoma responsive to temozolomide. J Neuro-Oncol 2004;70:73-75
Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW,
Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M. SD208, a novel TGF-β receptor I kinase inhibitor, inhibits growth and invasiveness
and enhances immunogenicity of murine and human glioma cells in vitro and in
vivo. Cancer Res 2004;64:7954-7961
Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, Weller M. RNA
interference targeting TGF-β1,2 enhances NKG2D-mediated anti-glioma immune
response, inhibits glioma cell migration and invasiveness and abrogates
tumorigenicity in vivo. Cancer Res 2004;64:7596-7603
Wick W, Wild-Bode C, Frank B, Weller M. BCL-2-induced glioma cell invasiveness
depends on furin-like proteases. J Neurochem 2004;91:1275-1283
Wick A, Wick W, Hirrlinger J, Gerhardt E, Dringen R, Dichgans J, Weller M, Schulz
JB. Chemotherapy-induced cell death in primary cerebellar granule neurons but
not in astrocytes: in vitro paradigm of differential neurotoxicity. J Neurochem
2004;91:1067-1074
Wick W, Küker W. Brain edema in neurooncology: radiological assessment and
management. Onkologie 2004;27:261-266
Wick W. Management unerwünschter Wirkungen der Chemotherapie maligner
Glioma. Onkologie Service 2004
Naumann U, Wick W, Beschorner R, Meyermann R, Weller M. Reply to Lorenz et
al.: Osteoprotegerin in the central nervous system. Acta Neuropathol
2004;107:578 (letter to the editor)
Uhl M, Weiler M, Wick W, Jacobs AH, Weller M, Herrlinger U. Migratory neural
stem cells for improved thymidine kinase-based gene therapy of malignant
gliomas. Biochem Biophys Res Commun 2005;328:125-129
Eyüpoglu IY, Hahnen E, Buslei R, Siebzehnrübl FA, Savaskan NE, Lüders M,
Christian Tränkle C, Wick W, Weller M, Fahlbusch R, Blümcke I. Suberoylanilide
hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in
vivo. J Neurochem 2005;93:992-999
Wick W, Weller M. How lymphotoxic is dose-intensified temozolomide? The
glioblastoma experience. J Clin Oncol 2005;23:4325-4326
Koch D, Wick W. Higher dosing of temozolomide? Regression of an anaplastic
oligoastrocytoma over more than three years. J Neurooncol 2005,77:219-220
7
50.
51.
52.
53.
54.
2006
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
2007
66.
Große-Hovest L, Wick W, Minoia R, Weller M, Rammensee H-G, Brem G, Jung G. A
„supra-agonistic“, bispecific single chain antibody purified from the serum of
cloned, transgenic cows induces T-cell mediated killing of glioblastoma cells in
vitro and in vivo. Int J Cancer 2005;117:1060-1064
Wick W, Menn O, Meisner C, Steinbach J, Hermisson M, Tatagiba M, Weller M.
Pharmacotherapy of epileptic seizures in brain tumor patients: who, when, why
and how long? Onkologie 2005;28:391-398
Tabatabai G, Bähr O, Möhle R, Eyüpoglu IY, Boehmler A, Wischhusen J, Dichgans J,
Blümcke I, Weller M, Wick W. Lessons from the bone marrow: how malignant
glioma cells attract adult hematopoietic stem cells. Brain 2005;128:2200-2211
Weiler M, Bähr O, Hohlweg U, Naumann U, Rieger J, Huang H, Tabatabai G, Krell
HW, Ohgaki H, Weller M, Wick W. Bcl-xL: time-dependent dissociation between
modulation of apoptosis and invasiveness in human malignant glioma cells. Cell
Death Differ 2006;13:1156-1169
Weller M, Steinbach JP, Wick W. Temozolomide, a milestone in the
pharmacotherapy of brain tumors. Future Oncol 2005;1:747-754
Steinbach JP, Blaicher H-P, Herrlinger U, Wick W, Nägele T, Meyermann R,
Tatagiba M, Bamberg M, Dichgans J, Karnath H-O, Weller M. Surviving glioblastoma
for more than 5 years: the patients’ perspective. Neurology 2006;66:239-42
Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B, Weller
M. MGMT and p53 status predict temozolomide sensitivity in human malignant
glioma cells. J Neurochem 2006;96:766-76
Eyüpoglu IY, Hahnen E, Tränkle C, Savaskan NE, Siebzehnrübl FA, Buslei R, Lemke
D, Wick W, Fahlbusch R, Blümcke I. Experimental therapy of malignant gliomas
using the inhibitor of class I histone deacetylase MS-275. Mol Cancer Ther
2006;5:1248-55
Roos WP, Batista LFZ, Naumann S, Wick W, Weller M, Menck CFM, Kaina B.
Apoptosis in glioma cells triggered by the temozolomide-induced DNA lesion O6methylguanine. Oncogene 2007;26:186-97
Tabatabai G, Frank B, Möhle R, Weller M, Wick W. Irradiation and hypoxia
promote homing of hematopoietic progenitor cells towards gliomas by TGF-βdependent HIF-1α-mediated induction of CXCL12. Brain 2006;129:2426-2435
Grassmé H, Jin J, Wilker B, von Kürthy G, Wick W, Weller M, Möröy T, Gulbins E.
Regulation of pulmonary Pseudomonas aeruginosa infection by the transcriptional
repressor Gfi1. Cellular Microbiology 2006;8:1096-1105
Naumann U, Bähr O, Wolburg H, Altenberend S, Wick W, Liston P, Ashkenazi A,
Weller M. Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma
cells and suppresses the growth of xenografts in nude mice. Gene Therapy
2007;14:147-61
Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann R-D, Steinbach JP,
Hundsberger T, Wick W, Meyermann R, Sommer C, Bamberg M, Reifenberger G,
Weller M. UKT-03 phase II trial of CCNU plus temozolomide chemotherapy in
addition to radiotherapy in newly diagnosed glioblastoma. J Clin Oncol
2006;24:4412-4417
Wick W, Naumann U, Weller M. Transforming growth factor-β: a molecular target
for the future therapy of glioblastoma. Curr Pharm Design 2006;12:341-349
Wick W, von Deimling A, Grabenbauer GG, Westphal M. Anaplastische Gliome
Standards und neue Entwicklungen in Diagnostik und Therapie. Der Onkologe
2006;12:508-518
Wick W, Kaufman A. Glioblastoma: what’s ischemia got to do with it? (Editorial)
Neurology 2006;67:1540-41
Mittelbronn M, Capper D, Bunz B, Dietz K, Goeppert B, Ajaaj R, Tabatabai G,
8
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
Stubenvoll F, Schlaszus H, Merseburger AS, Becker R, Freudenstein D, Wick W,
Weller M, Meyermann R, Simon P. De novo erythropoietin receptor (EPO-R)
expression in human neoplastic glial cells decreases with grade of malignancy but
is favourably associated with patient survival. Neuropathol Appl Neurobiol
2007;33:299-307
Tabatabai G, Frank B, Wick A, Lemke D, von Kürthy G, Obermüller U, Heckl S,
Christ G, Weller M, Wick W. Synergistic antiglioma activity of radiotherapy and
enzastaurin. Ann Neurol 2007;61:153-161
Vollmann H, Wölfel S, Ohneseit P, Stransky E, Vonthein R, Wick W, Meyermann R,
Simon P. Differential expression of Egr1 and activation of microglia following
irradiation in the rat brain. Strahlenther und Onkol 2007;183:248-255
Tran T-T, Uhl M, Ma JY, Janssen L, Sriram V, Aulwurm S, Kerr I, Lam A, Webb HK,
Kapoun AM, Kizer DE, McEnroe G, Hart B, Axon J, Murphy A, Chakravarty S, Dugar
S, Protter AA, Higgins LS, Wick W, Weller M, Wong DH. Inhibiting TGF-β signaling
restores immune surveillance in the SMA-560 glioma model. Neuro Oncol
2007;9:259-270
Burkhardt I, Tritschler F, Opitz CA, Frank B, Weller M, Wick W. Pirfenidone
inhibits TGF-β expression in malignant glioma cells. Biochem Biophys Res
Commun 2007;354;342-347
Rieger J, Frank B, Weller M, Wick W. Mechanisms of resistance of human glioma
cells to Apo2 ligand/TNF-related apoptosis-inducing ligand. Cell Physiol Biochem
2007;20:23-34
Roth P, Mittelbronn M, Meyermann R, Wick W, Weller M. Malignant glioma cells
counteract anti-tumor immune responses through expression of lectin-like
transcript-1. Cancer Res 2007;67:3540-3544
Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann
R, Reifenberger G, Weller M, Wick.W. Efficacy and tolerability of Temozolomide in
an one week on/one week off regimen in patients with recurrent glioma. J Clin
Oncol 2007;25:3357-3361
Platten M, Opitz C, Kohlhof P, Hegenbart U, Ho AD, Wick W. Painful neuropathy
due to intraneural metastases in a patient with acute myeloid leukaemia.
Neurology 2007;69:707
Wick W, Platten M. Brain tumor-related edema. Rivista medica 2007;13:1-3
Hacke W, Oertel W, Wick W, Hartung H-P, Ringleb PA, Diener, H-C. Die großen
klinischen Studien – Evidenzbasierte Medizin in der Deutschen Neurologie. Akt
Neurol 2007;34:386-389
Opitz CA, Wick W, Steinman L, Platten M. Tryptophan degredation in autoimmune
disease. Cell Mol Life Sci 2007;64:2542-63
2008
78.
79.
80.
Murat A, Migliavacca E, Gorlia T, Lambiv W, Shay T, Hamou M-F, de Tribolet N,
Regli L, Wick W, Kouwenhoven M, Hainfellner JA, Heppner FL, Dietrich P-Y,
Zimmer Y, Cairncross G, Janzer R-C, Domany E, Delorenzi M, Stupp R, Hegi ME.
Stem cell-related „self-renewal signature“ and high EGFR expression are
associated with resistance to concomitant chemoradiotherapy in glioblastoma. J
Clin Oncol 2008;26:3015-24
Wick W, Stupp R, Beule A-C, Bromberg J, Wick A, Ernemann U, Platten M, Marosi
C, Mason W, van den Bent M, Weller M, Rorden C, Karnath H-O. A novel tool to
analyse MRI recurrence patterns in glioblastoma. Neuro-oncol, 2008;10:1019-24
Tabatabai G, Herrmann C, Frank B, Möhle R, Mittelbronn M, Weller M, Wick W.
Glioma cell-mediated upregulation of CD62E on endothelial cells contributes to
glioma tropism of adult hematopoietic progenitor cells. Brain 2008;131:2579-95
9
81.
Rieger J, Maurer G, Frank B, Tabatabai G, Weller M, Wick W. Enzastaurin-induced
apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL . J
Neurochem 2008;106:2436-48
82.
Happold C, Roth P, Ernemann U, Wick W, Weller M, Schmidt F. Anticoagulation for
radiation-induced neurotoxicity revisited. J Neurooncol 2008;90:357-61
Hegi ME, Liu L, Herman JG, Stupp R, Wick W,
Weller M, Mehta MP, Gilbert MR. Correlation of MGMT Promoter Methylation With
Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT
Activity. J Clin Oncol 2008;26:4189-99
Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, Wick W.
Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma. Clin
Cancer Res 2008;14:2900-2908
Wick A, Wick W. Aktuelle Studienkonzepte in der Primär- und Rezidivtherapie.
Onkologie heute 2008;4:23-31
Eisele G, Roth P, Wick W, Weller M. MGMT in der klinischen Praxis. Onkologie
heute 2008;4:32-39
83.
84.
85.
86.
2009
87.
88.
89.
90.
91.
92.
93.
94.
95.
Maurer GD, Tritschler I, Adams B, Tabatabai G, Wick W, Stupp R, Weller M.
Cilengitide modulates attachment, invasiveness and viability of human glioma
cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro-oncol
2009;11:747-56
Wick A, Pascher C, Wick W, Jauch T, Weller M, Bogdahn U, Hau P. Rechallenge
with temozolomide in recurrent gliomas. J Neurol 2009;256:734-41
Broetz D, Hahn U, Maschke E, Wick W, Kueker W, Weller M. Lumbar disk prolapse:
Response to mechanical physiotherapy in the absence of changes in magnetic
resonance imaging. Report of 11 cases. NeuroRehabilitation 2008;23:289-94
Glas M, Happold C, Rieger J, Wiewrodt D, Bähr O, Steinbach JP, Wick W,
Kortmann R-D, Reifenberger G, Weller M, Herrlinger U. Long-term survival of
glioblastoma patients treated with radiotherapy and lomustine plus
temozolomide. J Clin Oncol 2009;27:1257-61
Happold C, Roth P, Wick W, Steinbach JP, Linnebank M, Weller M, Eisele G. ACNUbased chemotherapy for recurrent glioma in the temozolomide era. J Neurooncol
2009;92:45-8
Opitz CA, Litzenburger UM, Lutz C, Lanz TV, Tritschler I, Köppel A, Tolosa E,
Hoberg M, Anderl J, Aicher WK, Weller M, Wick W, Platten M. Toll-like receptor
engagement enhances the immunosuppressive properties of human bone marrowderived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via
interferon-beta and protein kinase R. Stem Cells 2009;27:909-19
Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC,
Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann R, Pietsch T,
Wiestler OD, Ernemann U, Bamberg M, v. Deimling A, Reifenberger G, Weller M,
for the Neurooncology Working Group (NOA) of the German Cancer Society. NOA04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic
Glioma With PCV or Temozolomide. J Clin Oncol 2009;27:5874-80
Tritschler I, Wick W, Keski-Oja H, Weller M. Modulation of TGF-βactivity by latent
TGF-β-binding protein 1 in human malignant glioma cells. Int J Cancer 2009
125:530-40
Ronellenfitsch MW, Burger MC, Brucker DP, Tritschler F, Rieger J, Wick W, Weller
M, Steinbach JP. Antagonism of the serine/threonine kinase mTOR selectively
mediates metabolic effects of EGFR inhibition and protects human malignant
glioma cells from hypoxia-induced cell death. Brain 2009 132:1509-22
10
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
Lanz TV, Opitz CA, Ho PP, Agrawal A, Weller M, Steinman L, Wick W, Platten M.
Mouse mesenchymal stem cells suppress antigen-specific TH-cell immunity
independent of indoleamine 2,3-dioxygenase 1 (IDO1). Stem Cells and Dev 2010;
19(5):657-68
Gramatzki D, Pantazis G, Schittenhelm J, Tabatabai G, Köhle C, Wick W, Schwarz
M, Weller M, Tritschler I. Aryl Hydrocarbon receptor inhibition down-regulates
TGF-β/Smad pathway in human glioblastoma cells. Oncogene 2009;28:2593-605
Brötz D, Maschke E, Burkard S, Engel C, Mänz C, Ernemann U, Wick W, Weller M.
Is there a role for benzodiazepines in the management of acute sciatica? Pain
2010;149:470-5
Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Mawrin
C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken J, Wesseling P,
Reifenberger G, von Deimling A. Type and frequency of IDH1 and IDH2 mutations
are related to astrocytic and oligodendroglial differentiation, grade and age: A
study of 1010 diffuse gliomas. Acta Neuropathol 2009;118:469-474
Wick W, Platten M, Weller M. New temozolomide regimens for the treatment of
glioma. Neuro-oncol 2009:11:69-79
Wick A, Weller M, Wick W. Molecular defined chemotherapies and targeted
therapies for malignant glioma. Onkopipeline 2008;1:11-17
Weller M, Wick W. Current therapeutic standards in malignant glioma.
Onkopipeline 2008;1:36-37
Platten M, Vogt-Schaden M, Löw S, Bendszus M, Weller M, Wick W. Therapy of
Primary CNS Lymphomas. Onkopipeline 2009;2:2-10
Weiler M, Whyte L, Hodecker S, Wick W. Challenges in Diagnosis and Treatment of
Recurrent Glioma: Novel Compounds and Therapeutic Use of Stem Cells.
Onkopipeline 2009;2:23-29
Schlegel U, Korfel A, Thiel E, Wick W, Kortmann R, Deckert M, Schackert G.
Primäre ZNS-Lymphome. Onkologe 2009;15:211-17
Wick W, Seidel C, Wick A, Platten M. Neurooncology in elderly patients.
Nervenheilkunde 2009;28:304-9
Wick W, Weller M. Classification and management of anaplastic gliomas. Curr
Opin Neurol 2009;22(6):650-6
2010
108.
109.
110.
111.
Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Bähr OR, Meyermann R,
Bamberg M, Tatagiba M, von Deimling A, Weller M, Wick W. Phase II trial of
radiochemotherapy with daily concomitant and adjuvant intensified (one week on
/ one week off) temozolomide plus indomethacin in newly diagnosed
glioblastoma: UKT-05. Int J Rad Biol Phys 2010;77:670-6
Wick W, Puduvalli VK, Chamberlain M, van den Bent MJ, Carpentier A, Cher L,
Mason W, Weller M, Hong S, Musib L, Leipa A, Thornton D, Fine H. Enzastaurin
(ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial
glioblastoma: a phase III study. J Clin Oncol 2010;28:1168-74
Wick A, Schäfer N, Dörner N, Schemmer D, Platten M, Bendszus M, Wick W.
Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation
with clinical outcome. J Neuroonc 2010;97:157-8
Rieken S, Gaiser T, Mohr A, Welzel T, Witt O, Kulozik AE, Wick W, Debus J, Combs
SE. Outcome and prognostic factors after radiation therapy for desmoplastic
medulloblastoma. BMC Cancer 2010 doi:10.1186/1471-2407-10-450
11
112.
113.
114.
115.
116.
117.
118.
119.
Wen PY, Macdonald DA, Reardon DA, Cloughesy TM, Sorensen AG, Galanis E,
DeGroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET,
Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang
SM. Updated Response Assessment Criteria For High-Grade Gliomas: Response
Assessment in Neuro-Oncology (RANO) Working Group. J Clin Oncol 2010;28:196372
Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman
AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP,
Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. Clinical trial end points for
high-grade glioma: the evolving landscape. Neuro Oncol 2011;13:353-61
Berger B, Capper D, Lemke D, Pfenning P-N, Platten M, Weller M, von Deimling A,
Wick W, Weiler M. Defective p53 antiangiogenic signaling in glioblastoma. Neuro
Oncol 2010;12:894-907
Wick A, Dörner N, Schäfer N, Hofer S, Schemmer D, Weller M, Platten M, Bendszus
M, Wick W. Bevacizumab does not increase the risk of remote relapse in malignant
glioma. Ann Neurol 2011;69:586-92
Tabatabai G, Hasenbach K, Herrmann C, Maurer G, Möhle R, Marini P, Grez M,
Wick W, Weller M. Glioma tropism of lentivirally transduced hematopoietic
progenitor cells. Int J Oncol 2010;36:1409-17
Soffietti R, Baumert B, Bello L, von Deimling A, Duffau H, Frénay M, Grisold W,
Grant R, Graus F, Hoang-Xuan K, Klein M, Melin B, Rees J, Siegal T, Smits A, Stupp
R, Wick W. Guidelines on management of lowgrade gliomas: report of an EFNSEANO* task force. Eur J Neurol 2010;17:1124-33
Roth P, Junker M, Tritschler I, Mittelbronn M, Dombrowski Y, Breit SN, Tabatabai
G, Wick W, Weller M, Wischhusen J. GDF-15 Contributes to Proliferation and
Immune Escape of Malignant Gliomas. Clin Cancer Res 2010;16: 3851-9
Heiland S, Wick W, Bendszus M. Perfusion MRI for parametric response maps in
tumors: is it really that easy? J Clin Oncol 2010;28:e591
120.
Rieken S, Mohr A, Habermehl D, Welzel T, Lindel K, Witt O, Kulozik AE, Wick W,
Debus J, Combs SE. Outcome and prognostic factors of radiation therapy for
medulloblastoma. Int J Radiat Oncol Biol Phys 2010;10:450
121.
Weller M, Stupp R, Reifenberger G, Brandes A, van den Bent MJ, Wick W, Hegi M.
MGMT promoter methylation in malignant gliomas: molecular neuropathology
ready for personalized medicine? Nat Rev Neurol 2010;6:39-51
122.
Wick W, Weller M, van den Bent M, Stupp R. Avastin and recurrent malignant
gliomas: a European perspective. J Clin Oncol 2010;28:188-189
Roth P, Wick W, Weller M. Steroids in neurooncology: actions, indications, side
effects. Curr Opinion Neurol 2010;23:597-602
Tabatabai G, Stupp R, van den Bent MJ, Hegi ME, Tonn JC, Wick W, Weller M.
Molecular Diagnostics of Gliomas: the Clinical Perspective. Acta Neuropathol
2010;120:585-592
Ronellenfitsch MW, Steinbach JP, Wick W. Epidermal growth factor receptor and
mammalian target of rapamycin as therapeutic targets in malignant glioma:
current clinical status and perspectives. Targeted Oncology 2010;5:183-191
123.
124.
125.
126.
127.
Weller M, Wick W, Hegi ME, Stupp R, Tabatabai G. Should biomarkers be used to
design personalized medicine for the treatment of glioblastoma? Future Oncol
2010;6:1406-1414
Wick W, Weller M. Anaplastic glioma: Neuropathology, molecular diagnostics and
current study concepts. Nervenarzt 2010;81(8):928-30, 932-5. doi:
10.1007/s00115-010-2956-1
2011
12
128.
Opitz CA, Litzenburger UM, Opitz U, Sahm F, Ochs K, Lutz C, Wick W, Platten M.
The Indoleamine-2,3-dioxygenase (IDO) inhibitor 1-Methyl-D-tryptophan
upregulates IDO1 in human cancer cells. Plos One 2011;6(5):e19823
129.
Combs SE, Kieser M, Rieken S, Habermehl D, Jäkel O, Haberer T, Nikoghosyan A,
Haselmann R, Unterberg A, Wick W, Debus J. Randomized Phase II study
Evaluating a Carbon Ion Boost applied after Combined Radiochemotherapy with
Temozolomide versus a Proton Boost after Radiochemotherapy with
Temozolomide in Patients with Primary Glioblastoma - The CLEOPATRA Trial. BMC
Cancer 2010;10:478
Grauer O, Pascher C, Hartmann C, Zeman F, Weller M, Proescholdt M, Brawanski
A, Pietsch T, Wick W, Bogdahn U, Hau P. Neoadjuvant temozolomide and 13-cis
retinoic acid treatment in patients with anaplastic gliomas (RNOP-05). J
Neurooncol 2011;104:801-9
Combs SE, Burkholder I, Edler L, Rieken S, Habermehl D, Jäkel O, Haberer T,
Haselmann R, Unterberg A, Wick W, Debus J. Carbon Ion Radiotherapy versus
Fractionated Stereotactic Radiotherapy in Patients with Recurrent or Progressive
Gliomas: The CINDERELLA Trial. BMC Cancer 2010;10:533
Radbruch A, Bendszus M, Wick W, Heiland S. Pitfalls in perfusion MRI in brain
tumors. Clinical Neuroradiology 2010;20:183-4
Eisele G, Roth P, Hasenbach K, Aulwurm S, Wolpert F, Tabatabai G, Wick W,
Weller M. APO010, a synthetic hexameric CD95 ligand, induces human glioma cell
death in vitro and in vivo. Neuro Oncol 2011;13:155-64
130.
131.
132.
133.
134.
135.
Seidel C, Dörner N, Osswald M, Wick A, Platten M, Bendszus M, Wick W. Does age
matter? - An MRI study on peritumoral edema in newly diagnosed primary
glioblastoma. BMC Cancer 2011;11:127
Combs SE, Rieken S, Wick W, Abdollahi A, von Deimling A, Debus J, Hartmann C.
Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step
forward, and one step back? Radiat Oncol 2011 13;6:115
136.
Hofer S, Elandt K, Greil R, Hottinger AF, Huber U, Lemke D, Marosi C, Ochsenbein
A, Pichler J, Roelcke U, Weder P, Zander T, Wick W, Weller M. Clinical outcome
with bevacizumab in patients with recurrent high-grade glioma treated outside
clinical trials. Acta Oncol 2011;50:630-5
137.
Combs SE, Edler L, Burkholder I, Rieken S, Habermehl D, Jäkel O, Haberer T,
Unterberg A, Wick W, Debus J, Haselmann R. Treatment of patients with atypical
meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with
postoperative photon radiotherapy: the MARCIE trial. BMC Cancer 2010;10:615
Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, Schnell O, Westphal
M, Wick W, Pietsch T, Loeffler M, Weller M, for the German Glioma Network.
Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.
Int J Cancer 2012;131(6):1342-50. doi: 10.1002/ijc.27385
Brockschmidt A, Trost D, Peterziel H, Zimmermann K, Pfenning P, Ehrler M,
Grassmann H, Waha A, Stabenow D, Brockschmidt F, Hoischen A, Kalla C, Waha A,
Seifert G, Knolle P, Latz E, Wick W, Hans V, Pfeifer A, Angel P, Weber R.
KIAA1797/FOCAD encodes a novel focal adhesion protein with tumor suppressor
function in gliomas. Brain 2012;135:1027-41
Ahmadi R, Stockhammer F, Becker N, Hohlen K, Misch M, Christians A, Dictus C,
Herold-Mende C, Capper D, Unterberg A, von Deimling A, Wick W, Hartmann C. No
prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. J
Neurooncol 2012 109(1):15-22. doi: 10.1007/s11060-012-0863-y
Lemke D, Pfenning PN, Sahm F, Klein AC, Kempf T, Warnken U, Schnölzer M,
Tudoran R, Weller M, Platten M, Wick W. Costimulatory Protein 4IgB7H3 Drives the
Malignant Phenotype of Glioblastoma by Mediating Immune Escape and
Invasiveness. Clin Cancer Res 2012;18:105-17
138.
139.
140.
141.
13
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.
Hertenstein A, Litzenburger U, Schumacher T, Opitz CA, Falk CS, Serafini T, Wick
W, Platten M. Suppression of human CD4+ T cell activation by 3,4dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and
CXCL10. Biochem Pharmacol 2011;82:632-41
Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T,
Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C,
Radlwimmer B, Lehman I, von Deimling A, Wick W, Platten M. An endogenous
ligand of the human aryl hydrocarbon receptor promotes tumor formation. Nature
2011;478:197-203
Nagel AM, Bock M, Hartmann C, Gerigk L, Neumann JO, Weber MA, Bendszus M,
Radbruch A, Wick W, Schlemmer HP, Semmler W, Biller A. The Potential of
Relaxation-Weighted Sodium Magnetic Resonance Imaging as Demonstrated on
Brain Tumors. Invest Radiol 2011;46:539-547
Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M,
Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von
Deimling A. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse
prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for
the unfavorable prognostic effect of higher age: implications for classification of
gliomas. Acta Neuropathol 2010;120:707-18
Radbruch A, Lutz K, Wiestler B, Bäumer P, Heiland S, Wick W, Bendszus M.
Relevance of T2 signal changes in the assessment of progression of glioblastoma
according to the Response Assessment in Neurooncology criteria. Neuro Oncol
2012;14:222-9. Dec 6 2011
Wick W, Weller M, Weiler M, Batchelor T, Yung AWK, Platten M. Pathway
inhibition: Emerging molecular targets for treating glioblastoma. Neuro Oncol
2011;13:566-79
Weller M, Wick W, von Deimling A. Isocitrate dehydrogenase mutations: a
challenge to traditional views on the genesis and malignant progression of
gliomas. Glia 2011;59:1200-4
Wick W, Wick A, Weiler M, Weller M. Patterns of Progression in Malignant Glioma
Following Anti-VEGF Therapy: Perceptions and Evidence. Current Neurology and
Neuroscience Reports 2011;11:305-12.
Weller M, Wick W. "Nanomania" ante portas of neurooncology? J Neurooncol 2010
Dec 25
Weller M, Wick W. Are we ready to demystify age in glioblastoma? Or does older
age matter in glioblastoma? Neuro Oncol 2011;13: 365-366
152.
Weller M, Platten M, Roth P, Wick W. Geriatric neuro-oncology: from mythology to
biology. Curr Opin Neurol 2011;24:599-604
153.
Wick W, Weller M. Trabedersen to target transforming growth factor-beta: when
the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology
2011;13:132-142). Neuro Oncol 2011;13:559-60; author reply 561-2
Tabatabai G, Wick W, Weller M. Stem cell-mediated gene therapies for malignant
gliomas: a promising targeted therapeutic approach? Discov Med 2011;11:529-36
154.
155.
156.
157.
Wick W. Anaplastic gliomas: an emerging entity. Eur J Cancer 2011;47 Suppl
3:S357-8
Brandes AA, Franceschi E, Gorlia T, Wick W, Jacobs AH, Baumert BG, van den
Bent M, Weller M, Stupp R; On behalf of European Organisation for Research and
Treatment of Cancer Brain Tumour Group. Appropriate end-points for right results
in the age of antiangiogenic agents: Future options for phase II trials in patients
with recurrent glioblastoma. Eur J Cancer 2012;48(6):896-903. EPub 2011 Nov 23
Wick W, Blaes J, Weiler M. mTORC 2:1 for Chemotherapy Sensitization in
Glioblastoma. Cancer Discov 2011;1:475-6.
14
2012
158.
Platten M, Litzenburger U, Wick W. The aryl hydrocarbon receptor in tumor
immunity. OncoImmunology 2012 May 1;1(3):396-397.
159.
Platten M, Opitz C, Wick W. The aryl hydrocarbon receptor as a promoter of
malignant glioma. Cell Cycle 2012;15;11(4):643-4
160.
Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G,
Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper M, Braun C, Meixensberger J,
Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M, for the Neurooncology
Working Group (NOA) of the German Cancer Society Chemotherapy versus
radiotherapy for malignant astrocytoma in the elderly. Lancet Oncol
2012,13(7):707-15
Weiler M, Pfenning P-N, Thiepold A-L, Blaes J, Jestaedt L, Gronych J, Dittmann LM,
Berger B, Jugold M, Kosch M, Combs SE, von Deimling A, Weller M, Bendszus M,
Platten M, Wick W. Suppression of Proinvasive RGS4 by mTOR Inhibition Optimizes
Glioma Treatment. Oncogene Epub 2012 May 7; 2013 Feb 28;32(9):1099-109
Beynon C, Hoffmann T, Wick W, Unterberg AW, Kiening KL. Stereotactic brainstem
biopsy in a patient with coagulopathy of unclear etiology: case report. Minim
Invasive Neurosurg 2011;54:268-70
161.
162.
163.
164.
165.
166.
167.
168.
Christians A, Hartmann C, Benner A, Meyer J, von Deimling A, Weller M, Wick W,
Weiler M. Prognostic value of three different methods of MGMT promoter
methylation analysis in a prospective trial on newly diagnosed glioblastoma. Plos
One 2012;7(3):e33449
Happold C, Roth P, Wick W, Schmidt N, Florea A-M, Reifenberger G, Weller M.
Distinct molecular mechanisms of acquired resistance to temozolomide in
glioblastoma cells. J Neurochem 2012;122(2):444-55
Seidel C, Hentschel B, Simon M, Schnell O, Heese O, Tatagiba M, Krex D,
Reithmeier T, Kowoll A, Weller M, Wick W. A comprehensive analysis of vascular
complications in 3889 glioma patients from the German Glioma Network. J Neurol
2013;260(3):847-55 Epub 2012 Oct 27
Wiestler B, Claus R, Hartlieb SA, Schliesser MG, Weiss EK, Hielscher T, Platten M,
Dittmann LM, Meisner C, Felsberg J, Happold C, Simon M , Nikkhah G, Papsdorf K,
Steinbach JP, Sabel M, Grimm C, Weichenhan D, Tews B, Reifenberger G, Capper
D, Müller W, Plass C, Weller M, Wick W for the Neurooncology Working Group
(NOA) of the German Cancer Society. Malignant gliomas of elderly patients have a
distinct molecular profile: An analysis of the NOA-08 study collective. Neurooncol
2013;15(8):1017-26
Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC,
Koeppen S, Ketter R, Weiler M, Tabatabai G, v. Deimling A, Gramatzki D, Westphal
M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M. IDH1 mutations
determine the prognostic versus predictive value of MGMT promoter methylation
in malignant gliomas. Neurology 2013;81(17):1515-22
Combs SE, Edler L, Rausch R, Welzel T, Wick W, Debus J. Generation and
validation of a prognostic score to predict outcome after re-irradiation of
recurrent glioma. Acta Oncol 2013;52(1):147-52 EPub 2012 Jun 11.
15
169.
170.
171.
172.
173.
174.
175.
176.
177.
178.
179.
180.
181.
182.
Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E,
Tönjes M, Sill M, Bender S, Kool M, Zapatka M, Becker N, Zucknick M, Hielscher T,
Liu XY, Fontebasso AM, Ryzhova M, Albrecht S, Jacob K, Wolter M, Ebinger M,
Schuhmann MU, van Meter T, Frühwald MC, Hauch H, Pekrun A, Radlwimmer B,
Niehues T, von Komorowski G, Dürken M, Kulozik AE, Madden J, Donson A,
Foreman NK, Drissi R, Fouladi M, Scheurlen W, von Deimling A, Monoranu C,
Roggendorf W, Herold-Mende C, Unterberg A, Kramm CM, Felsberg J, Hartmann C,
Wiestler B, Wick W, Milde T, Witt O, Lindroth AM, Schwartzentruber J, Faury D,
Fleming A, Zakrzewska M, Liberski PP, Zakrzewski K, Hauser P, Garami M, Klekner
A, Bognar L, Morrissy S, Cavalli F, Taylor MD, van Sluis P, Koster J, Versteeg R,
Volckmann R, Mikkelsen T, Aldape K, Reifenberger G, Collins VP, Majewski J,
Korshunov A, Lichter P, Plass C, Jabado N, Pfister SM. Hotspot Mutations in H3F3A
and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma.
Cancer Cell 2012;22:425-37
Ott M, Litzenburger UM, Sahm F, Rauschenbach KJ, Tudoran R, Hartmann C,
Marquez VE, von Deimling A, Wick W, Platten M. Promotion of Glioblastoma Cell
Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor
Kinase. PLoS One 2012;7:e47663
Radbruch A, Lutz K, Bäumer P, Wiestler B, Weiler M, Röthke M, Schlemmer HP,
Heiland S, Wick W, Bendszus M. Differentiation of Glioblastoma and Primary CNS
Lymphoma Using Susceptibility Weighted Imaging. European Journal of Radiology
2013;82(3):552-6
Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, Marosi C,
Zielinski C, Mehta MP, Winkler F, Wick W, von Deimling A. Brain metastases:
pathobiology and emerging targeted therapies. Acta Neuropathol 2012;123:205-22
Weller M, Stupp R, Hegi M, Wick W. Individualized targeted therapy for
glioblastoma: fact or fiction? Cancer J 2012;18:40-4
Platten M, Wick W, van den Eynde B. Tryptophan catabolism in cancer: Beyond
IDO and tryptophan depletion. Cancer Res 2012 72(21):5435-40
Weller M, Stupp R, Wick W. Epilepsy meets Cancer: when, why, and what to do
about it? Lancet Oncol 2012;13:e375-82
Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen PY, Reardon DA, Wick W,
Macdonald D, Armstrong TS, Weller M, Vogelbaum M, Colman H, Sargent DJ, van
den Bent MJ, Gilbert M, Chang S. Phase 2 trial design in neuro-oncology revisited:
a report from the RANO group. Lancet Oncol 2012;13:e196-204.
Reardon DA, Perry JR, Brandes AA, Jalali R, Wick W. Advances in malignant glioma
drug discovery. Expert Opin Drug Discov 2011;6:739-53
Wick W, Weller M for the NOA-08 Study Group. Response to Chamberlain and
Fiorentina et al. on The NOA-08 randomized phase III trial of chemotherapy versus
radiotherapy for malignant astrocytoma in the elderly. Lancet Oncol 2012 (Letter
to the Editor)
Weiler M, Wick W. Molecular predictors of outcome in low-grade glioma. Current
Opinion in Neurology 2012;25:767-73.
Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson M, Wick W,
Reifenberger G. Personalized care in neuro-oncology coming of age: why we need
MGMT and 1p/19q testing for malignant glioma patients inclinical practice. Neuro
Oncol 2012;14 Suppl 4:iv100-8
Platten M, Wick W. Treatment of brain tumor patients: Hyperthermia, hyperbaric
oxygenation, electric fields or nanoparticles. Nervenarzt 2012;83:982-7.
Laperriere N, Weller M, Stupp R, Perry JR, Brandes AA, Wick W, van den Bent MJ.
Optimal management of elderly patients with glioblastoma. Cancer Treat Rev
2013;39(4):350-7 EPub 2012 Jun 19.
2013
16
183.
Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of
recurrent glioblastoma—are we there yet? Neuro Oncol 2013;15:4-27.
184.
RTOG 9802: good wines need aging. van den Bent MJ, Baumert B, Jaeckle K, Wick
W. J Clin Oncol 2013;31(5):653-4
185.
Radbruch A, Wiestler B, Sahm F, Heiland S, Röthke M, Wick W, Schlemmer H-P,
Bendszus M. Quantitative susceptibility mapping differentiation between blood
depositions and calcifications in patients with glioblastoma. Plos One
2013;8(3):e57924
Seystahl K, Wiestler B, Hundsberger T, Happold C, Wick W, Weller M, Wick A.
Bevacizumab Alone or in Combination with Irinotecan in Recurrent WHO Grade II
and Grade III Gliomas. Eur Neurol 2013;69:95-101.
186.
187.
Sahm F, Opitz CA, Radlwimmer B, von Deimling A, Bode HB, Wick W, Platten M.
The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers
resistance of gliomas to oxidative stress. Cancer Res 2013;73(11):3225-34
188.
Domhan S, Schwager C, Wei Q, Muschal S, Sommerer C, Morath C, Wick W,
Maercker C, Debus J, Zeier M, Huber PE, Abdollahi A. Deciphering the systems
biology of mTOR inhibition by integrative transcriptome analysis. Curr Pharm Des
2013 Mar 19
Wick W, Steinbach JP, Platten M, Hartmann C, Wenz F, von Deimling A, Shei P,
Moreau-Donnet V, Stoffregen C, Combs SE. Enzastaurin Before and Concomitant
with Radiation Therapy, Followed by Enzastaurin Maintenance Therapy, in Patients
with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation.
Neuro Oncol 2013;15(10):1405-12
Goeppert B, Schmidt CR, Geiselhart L, Dutruel C, Capper D, Renner M, Vogel MN,
Zachskorn C, Zinke J, Campos B, Schmezer P, Popanda O, Wick W, Weller M,
Meyermann R, Schittenhelm J, Harter PN, Simon P, Weichert W, Schirmacher P,
Plass C, Mittelbronn M. Differential Expression of the Tumor Suppressor A Kinase
Anchor Protein 12 (AKAP12) in Human Diffuse and Pilocytic Astrocytomas Is
Regulated by Promoter Methylation. J Neuropath Exp Neurol 2013;72(10):933-41
Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM,
Platten M, Weller M, Wick W. ATRX loss refines the classification of anaplastic
gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better
prognosis. Acta Neuropathol 2013;126(3):443-51
Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment
paradigm and current controversies. Curr Treat Options Oncol 2013;14(4):505-13
189.
190.
191.
192.
193.
194.
195.
Lanz TV, Becker S, Osswald M, Bittner S, Schuhmann MK, Opitz CA, Gaikwad S,
Wiestler B, Litzenburger UM, Sahm F, Ott M, Iwantscheff S, Grabitz C, Mittelbronn
M, von Deimling A, Winkler F, Meuth SG, Wick W, Platten M. Protein kinase Cβ as
a therapeutic target stabilizing blood-brain barrier disruption in experimental
autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2013;110(36):14735-40
Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D,
Dippel E, Eigentler T, Feyer P, Follmann M, Frerich B, Ganten MK, Gärtner J,
Gutzmer R, Hassel J, Hauschild A, Hohenberger P, Hübner J, Kaatz M, Kleeberg
UR, Kölbl O, Kortmann RD, Krause-Bergmann A, Kurschat P, Leiter U, Link H,
Loquai C, Löser C, Mackensen A, Meier F, Mohr P, Möhrle M, Nashan D, Reske S,
Rose C, Sander C, Satzger I, Schiller M, Schlemmer HP, Strittmatter G,
Sunderkötter C, Swoboda L, Trefzer U, Voltz R, Vordermark D, Weichenthal M,
Werner A, Wesselmann S, Weyergraf AJ, Wick W, Garbe C, Schadendorf D.M
alignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". J
Dtsch Dermatol Ges. 2013;11 Suppl 6:1-116, 1-126
Ochs K, Sahm F, Opitz CA, Lanz TV, Oezen I, Couraud PO, von Deimling A, Wick W,
Platten M. Immature mesenchymal stem cell-like pericytes as mediators of
immunosuppression in human malignant glioma. J Neuroimmunol 2013;265(1-
17
2):106-16
196.
Reinert C, Kremmler L, Burock S, Bogdahn U, Wick W, Gleiter CH, Koller M, Hau P.
Quantitative and qualitative analysis of study-related patient information sheets
in randomised neuro-oncology phase III-trials. Eur J Cancer 2013 Oct 5
197.
Lutz K, Wiestler B, Graf M, Bäumer P, Floca R, Schlemmer HP, Heiland S, Wick W,
Bendszus M, Radbruch A. Infiltrative patterns of glioblastoma: Identification of
tumor progress using apparent diffusion coefficient histograms. J Magn Reson
Imaging 2013 Sep 30
Tabatabai G, Stupp R, Wick W, Weller M. Malignant astrocytoma in elderly
patients: where do we stand? Curr Opin Neurol 2013;26(6):693-700
198.
199.
200.
201.
202.
203.
204.
205.
Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DT, Kool M, Northcott PA,
Wiestler B, Böhmer K, Meyer J, Mawrin C, Hartmann C, Mittelbronn M, Platten M,
Brokinkel B, Seiz M, Herold-Mende C, Unterberg A, Schittenhelm J, Weller M,
Pfister S, Wick W, Korshunov A, von Deimling A. Distribution of TERT promoter
mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol
2013;126(6):907-15.
Wick W, Wick A, Platten M. Good maths is needed to understand CMV data in
glioblastoma.
Int J Cancer 2013 Nov 18
Han K, Ren M, Wick W, Abrey L, Das A, Jin J, Reardon DA. Progression-free survival
as a surrogate endpoint for hazard ratio and median overall survival in
glioblastoma: a literature-based meta-analysis from 91 trials. Neuro Oncology
2013 Dec 12.
Kickingereder P, Wiestler B, Sahm F, Deike K, Heiland S, Roethke M, Schlemmer HP, Wick W, Bendszus M, Radbruch A. Multiparametric differentiation of primary
CNS lymphoma and atypical glioblastoma using diffusion-, perfusion-, and
susceptibility-weighted MRI. Radiology in press
Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, Bunse L, Solecki G,
Eichwald V, Jugold M, Hodecker SC, Osswald M, Meisner C, Hielscher T, Rübmann P,
Pfenning P-N, Ronellenfitsch M, Kempf T, Schnölzer M, Abdollahi A, Lang F,
Bendszus M, von Deimling A, Winkler F, Weller M, Vajkoczy P, Platten M, Wick W.
The mTOR target NDRG1 confers MGMT-dependent resistance to alkylating
chemotherapy. Proc Natl Acad Sci USA 2013 Dec 23
Wick W, Wick A, Platten M. Challenging (the) CMV data in glioblastoma. Neuro
Oncol 2013 Dec 18.
Wick W, Platten M, Reifenberger G, Weller M. Molecular Subtyping of Anaplastic
Gliomas. Neurology in press (letter)
2014
206.
207.
208.
Nowosielski M, Wiestler B, Goebel G, Hutterer M, Schlemmer HP, Stockhammer G,
Wick W, Bendszus M, Radbruch A. Progression types after anti-angiogenic therapy
are related to outcome in recurrent glioblastoma. Neurology April 11 2014
Weller M, Wick W. Neuro-oncology in 2013: Improving outcome in newly diagnosed
malignant glioma. Nat Rev Neurol 2014;10:68-70.
Blaes J, Weiler M, Sahm F, Hentschel B, Osswald M, Czabanka M, Thomé CM,
Schliesser MG, Pusch S, Luger S, Winkler F, Radbruch A, Jugold M, Simon M,
Steinbach JP, Schackert G, Tatagiba M, Westphal M, Tonn JC, Gramatzki D, Pietsch
T, Hartmann C, Glimm H, Vajkoczy P, von Deimling A, Platten M, Weller M, Wick W.
NDRG1 prognosticates the natural course of disease in WHO grade II glioma. J
Neurooncol 2014;117:25-32
18
209.
Eisele G*, Wick A*, Eisele A-C, Clement PM, Tonn J-C, Tabatabai G, Ochsenbein A,
Schlegel U, Neyns B, Krex D, Simon M, Nikkhah G, Picard M, Stupp R, Wick W, Weller
M. Cilengitide treatment of newly diagnosed glioblastoma patients does not alter
patterns of progression. J Neurooncol 2014;117:141-145
210.
Wiestler B, Radbruch A, Osswald M, Combs SE, Jungk C, Winkler F, Bendszus M,
Unterberg A, Platten M, Wick W, Wick A. Towards optimizing the sequence of
bevacizumab and nitrosoureas in recurrent malignant glioma. J Neuroonc
2014;117:85-92
211.
Wick W, Platten M. CMV infection and glioma, a highly controversial concept
struggling in the clinical arena. Neuro Oncol 2014;16:332-3.
Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-JonathanMoyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G,
Soffietti R, Wick W, for the European Association for Neuro-Oncology (EANO) Task
Force on Malignant GliomaEANO Guideline on the Diagnosis and Treatment of
Malignant Glioma. The Lancet Oncology accepted
212.
213.
214.
215.
216.
217.
218.
219.
220.
221.
Kickingereder P, Sahm F, Wiestler B, Röthke M, Heiland S, Schlemmer H-P, Wick
W, von Deimling A, Bendszus M, Radbruch A.Evaluation of microvascular
permeability with dynamic contrast-enhanced MRI for the differentiation of
primary CNS lymphoma and glioblastoma: radiologic-pathologic correlation. Am J
Neuroradiol 2014 April 10
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF,
Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T.
Bevacizumab Plus Radiotherapy/Temozolomide for Newly Diagnosed Glioblastoma.
New Engl J Med 2014; 370:709-722.
Platten M, Ochs K, Lemke D, Opitz C, Wick W. Microenvironmental clues for
glioma immunotherapy. Curr Neurol Neurosci Rep 2014;14:440
Zhu Z, Khan MA, Weiler M, Jonas Blaes J, Jestaedt L, Zou P, Gronych J, Bernhardt O,
Korshunov A, Lichter P, Radlwimmer B, Heiland S, Bendszus M, Wick W, Liu H-K.
Targeting Self-renewal in High-Grade Brain Tumors Leads to Loss of Brain Tumor
Stem Cells and Prolonged Survival. Cell Stem Cells 2014 in press
Reifenberger G, Weber RG, Riehmer V, Kaulich K, Willscher E, Wirth H, Gietzelt J,
Hentschel B, Westphal M, Simon M, Schackert G, Schramm J, Matschke J, Sabel
MC, Gramatzki D, Felsberg J, Hartmann C, Steinbach JP, Schlegel U, Wick W,
Radlwimmer B, Pietsch T, Tonn JC, von Deimling A, Binder H, Weller M, Loeffler
M; for the German Glioma Network. Molecular characterization of long-term
survivors of glioblastoma using genome- and transcriptome-wide profiling. Int J
Cancer 2014 Mar 11.
Letter to the Editor. Chinot O, Wick W, Cloughesy T. New Engl J Med 2014;
Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, Plass C,
Hegi M, Platten M, Reifenberger G. MGMT testing in neurooncology - A paradigm
for prospects and challenges of biomarker-based treatment decisions. Nat Rev
Neurol 2014; in press
Litzenburger UM, Opitz CA, Sahm F, Rauschenbach KJ, Trump S, Winter M, Ott M,
Ochs K, Lutz C, Liu X, Anastasov N, Lehmann I, Höfer T, von Deimling A, Wick W,
Platten M. Constitutive IDO expression in human cancer is sustained by an
autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget. 2014 Jan
20.
Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald
M, Oezen I, Ott M, Keil M, Balss J, Rauschenbach K, Grabowska AK, Vogler I,
Diekmann J, Trautwein N, Eichmüller S, Okun J, Stefanovic S, Riemer AB, Sahin U,
Friese M, Beckhove P, von Deimling A, Wick W, Platten M (2014). A vaccine
targeting mutant IDH1 induces antitumor immunity. Nature accepted
19